maintain equal weight rate share
regeneron increas price target
unchang multipl forward ep vs current year
ep follow retin expert call seri assess near term impact
anti-vegf therapeut eylea longer term market
dynam follow safeti issu competitor beovu overal
eylea benefit longer term vascul concern
around beovu wet believ near term impact
eylea volum under-estim could
weigh share forese futur potenti
eylea volum reduct believ
particularli sensit disrupt despit effort
provid solut kevzara monoclon antibodi
cocktail reduc eylea sale estimate
versu consensu non-gaap ep estim
versu consensu ep vs
prior ep vs prior
well fargo biotechnolog team conduct dilig call
anti-vegf practic across impact region california
illinoi florida massachusett expert call cover
academ privat retin practic suggest greater impact
academ outpati center larg privat
practic overal larg academ center report
prior anti-vegf inject volum wherea privat
practic report volum declin prior level case
outpati clinic academ practic close
oper room convert icu labil
patient refer commun clinic
case macular diseas treatment deem essenti
expert suggest patient reluct reinforc low volum
one estim return normal extend month longer
acknowledg risk accumul fluid impair vision
delay treatment expert feedback vari week
doubl baselin frequenc term patient toler
addit focu report vascul recent launch
regard sever vascular occlus degre vision loss
lack clear explan similar vasculopathi seen
anti-vegf agent accord expert patient
switch back eylea resolut inflamm
expert suggest increment benefit beovu eylea
initi use high hurdl describ novarti regain
trust safeti drug
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
compani data secur llc estim reuter
less impact academ center
overal clinic volum prior volum
anti-vegf inject volum prior volum
get patient quickli avoid patient wait
cushion miss inject limit patient alreadi trial dose extend
optim extend
exampl given patient unsuccess extend drop back
week cushion delay inject
macular diseas treatment deem essenti
colleagu outsid macular shut cataract surgeri
clinic oper capac
six-month checkup postpon
requir schedul inject come clinic patient elect postpon
current situat highlight need home oct although machin still prototyp stage
estim could take month get everyth back track
believ current restrict clinic trial need relax infect rate drop
april may summer new polici may come place
infect go expect everyth shut absent vaccin
beovu start use late decemb februari switch patient eylea
last week case sever inflamm luckili patient respond complet
report patient littl better beovu switch back
retin doc happi current portfolio anti-vegf agent suggest beovu
recoveri challeng novarti
still see patient focu urgent case
overal clinic prior volum inject clinic prior volum
eylea use stay steadi major wetamd dme patient keep regular inject
activ encourag patient come clinic follow strict guidelin
questionnair temperatur assess front door avoid clinic wait md
wear surgic mask patient
patient defer diabet retinopathi surgic follow-up dri mild
contact privat practic note optometrist shut refer patient
ophthalmologist retin specialist
switch patient beovu eylea
saw problem saw improv
macula meet data present even though problem note
practic beovu use stop abruptli switch patient back eylea
spoke colleagu patient want continu beovu recons major
colleagu stop use drug
unmet need retin specialist continu interest innov
suggest challeng situat novarti
chicago academ outpati center close may
hospit shut convert icu
academ center cancel appoint privat practic littl hand review
singl week see patient need emerg treatment
inject patient refer colleagu commun practic prior volum
privat practic colleagu see volum mostli need inject
patient report worri come closur patient schedul
show final week shutdown
cushion vision impair doubl regimen current week week go
without run problem
see benefit beovu beyond eylea start switch patient stop report
vascul
describ report pattern inflamm vascul occlus differ anyth seen
anti-vegf agent
pattern biolog rational guid safe use predict affect creat signific
hurdl novarti regain physician trust
return beovu novarti yet note colleagu
price target
arriv price target appli multipl ep estim believ
multipl appropri context estim long-term ep growth risk includ
reimburs risk eylea forc adopt low-cost avastin potenti safeti issu
eylea failur expand eylea beyond slower expect praluent launch litig risk
failur advanc pipelin candid
maintain equal weight rate given risk includ inabl sustain eylea growth
potenti competit retin diseas failur advanc key pipelin program
larg cap commercial-stag biotechnolog compani class lead biolog develop
engin translat speed flexibl address emerg area infecti
diseas immuno-oncolog
